Page 138 - 《中国药房》2024年7期

of hand，hip，and knee[J]. J Clin Rheumatol，2016，22（7）： 15（11）：1353.
345-354. [23] KUMAR M，KUMAR D，KUMAR S，et al. A recent re‐
[10] PAIK J，DUGGAN S T，KEAM S J. Triamcinolone ace‐ view on bio-availability enhancement of poorly water-
tonide extended-release：a review in osteoarthritis pain of soluble drugs by using bioenhancer and nanoparticulate
the knee[J]. Drugs，2019，79（4）：455-462. drug delivery system[J]. Curr Pharm Des，2022，28（39）：
[11] SHE P，BIAN S，CHENG Y Q，et al. Dextran sulfate- 3212-3224.
triamcinolone acetonide conjugate nanoparticles for tar‐ [24] TAULU R，NUMMINEN J，BIZAKI A，et al. Image-
geted treatment of osteoarthritis[J]. Int J Biol Macromol， guided，navigation-assisted Relieva Stratus MicroFlow
2020，158：1082-1089. spacer insertion into the ethmoid sinus[J]. Eur Arch Oto‐
[12] HABIB G，SAFIA A. The effect of intra-articular injection rhinolaryngol，2015，272（9）：2335-2340.
of betamethasone acetate/betamethasone sodium pho- [25] VANDEWALLE J，LUYPAERT A，DE BOSSCHER K，
sphate on blood glucose levels in controlled diabetic pa‐ et al. Therapeutic mechanisms of glucocorticoids[J]. Trends
tients with symptomatic osteoarthritis of the knee[J]. Clin Endocrinol Metab，2018，29（1）：42-54.
Rheumatol，2009，28（1）：85-87. [26] NANIWA M，NAKATOMI C，HITOMI S，et al. Analgesic
[13] KRAUS V B，CONAGHAN P G，AAZAMI H A，et al. Sy‐ mechanisms of steroid ointment against oral ulcerative
novial and systemic pharmacokinetics （PK） of triamcino‐ mucositis in a rat model[J]. Int J Mol Sci，2021，22（22）：
lone acetonide （TA） following intra-articular （IA） injec‐ 12600.
tion of an extended-release microsphere-based formula‐ [27] LAM J K，XU Y Y，WORSLEY A，et al. Oral transmuco‐
tion （FX006） or standard crystalline suspension in pa‐ sal drug delivery for pediatric use[J]. Adv Drug Deliv
tients with knee osteoarthritis （OA）[J]. Osteoarthr Carti‐ Rev，2014，73：50-62.
lage，2018，26（1）：34-42. [28] THANTAVIRIYA S， KAMANAMOOL N，
[14] 朱开元，徐翰南，王云，等. 关节腔内药物递送系统研究 SANSUREERUNGSIKUL T，et al. Efficacy and safety of
进展[J]. 国际骨科学杂志，2020，41（5）：271-274，302. detachable microneedle patch containing triamcinolone
ZHU K Y，XU H N，WANG Y，et al. Advances in intra- acetonide in the treatment of inflammatory acne[J]. Clin
articular drug delivery system[J]. Int J Orthop，2020，41 Cosmet Investig Dermatol，2023，16：1431-1441.
（5）：271-274，302. [29] YIM S G，SEONG K Y，THAMARAPPALLI A，et al.
[15] SEO B B，KWON Y，KIM J，et al. Injectable polymeric Fast-embeddable grooved microneedles by shear actuation
nanoparticle hydrogel system for long-term anti- for accurate transdermal drug delivery[J]. Pharmaceutics，
inflammatory effect to treat osteoarthritis[J]. Bioact Ma‐ 2023，15（7）：1966.
ter，2022，7：14-25. [30] QU X Y，GUO X L，ZHU T T，et al. Microneedle patches
[16] VALDES L M，SOBRIN L. Uveitis therapy：the corticoste‐ containing mesoporous polydopamine nanoparticles loaded
roid options[J]. Drugs，2020，80（8）：765-773. with triamcinolone acetonide for the treatment of oral
[17] DIKMETAS O，KUEHLEWEIN L，GELISKEN F. Re‐ mucositis[J]. Front Bioeng Biotechnol，2023，11：1203709.
bound phenomenon after intravitreal injection of triam‐ [31] PENG C L，LIU C，TANG X. Determination of physico‐
cinolone acetonide for macular edema[J]. Ophthalmo‐ chemical properties and degradation kinetics of triamcino‐
logica，2020，243（6）：420-425. lone acetonide palmitate in vitro[J]. Drug Dev Ind Pharm，
[18] KATO F，NOZAKI M，KATO A，et al. Retinal microvas‐ 2010，36（12）：1469-1476.
cular changes after intravitreal triamcinolone acetonide in [32] DISPHANURAT W，SIVAPORNPAN N，SRISANTITHUM
diabetic macular edema[J]. J Clin Med，2023，12（10）：3475. B，et al. Efficacy of triamcinolone acetonide-loaded dis‐
[19] JEAL W，FAULDS D. Triamcinolone acetonide. A review solving microneedle patch for the treatment of hypertro‐
of its pharmacological properties and therapeutic efficacy phic scars and keloids：a randomized，double-blinded，
in the management of allergic rhinitis[J]. Drugs，1997，53 placebo-controlled split-scar study[J]. Arch Dermatol Res，
（2）：257-280. 2023，315（4）：989-997.
[20] FORBES B，BOMMER R，GOOLE J，et al. A consensus [33] JANG M，KANG B M，YANG H，et al. High-dose steroid
research agenda for optimizing nasal drug delivery[J]. dissolving microneedle for relieving atopic dermatitis[J].
Expert Opin Drug Deliv，2020，17（2）：127-132. Adv Healthc Mater，2021，10（7）：e2001691.
[21] SALLAM M A，HELAL H M，MORTADA S M. Ra- [34] WANG H，FU Y X，LIU P，et al. Supramolecular dissol-
tionally designed nanocarriers for intranasal therapy of ving microneedle patch loading hydrophobic glucocorti‐
allergic rhinitis：influence of carrier type on in vivo nasal coid for effective psoriasis treatment[J]. ACS Appl Mater
deposition[J]. Int J Nanomedicine，2016，11：2345-2357. Interfaces，2023，15（12）：15162-15171.
[22] PEÑA M A. Solubilization and controlled release strategy （收稿日期：2023-08-04 修回日期：2024-03-17）
of poorly water-soluble drugs[J]. Pharmaceuticals，2022， （编辑：胡晓霖）

· 900 · China Pharmacy 2024 Vol. 35 No. 7 中国药房 2024年第35卷第7期